Abstract: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. A certain population of patients with MS present with a relapse-remitting disease course (RRMS) during the early phase and eventually advance to a progressive course (PMS). While immune modulation therapies have recently seen tremendous success in RRMS, our limited knowledge of pathogenesis hampers the development of effective treatments for PMS.